Summary
EVerZom has developed a patented, fast, cost-effective, large-scale standardized extracellular vesicles (EV) production process to address the manufacturing issues that hamper EV translation towards clinic. EVerZom has performed a successful platform scale-up to 6L, meeting quantities needed for phase I trials, placing it at least 2 years ahead of known competitors.
With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities. Hence, EVerZom intends to achieve key milestones during the next 2 years including the validation of platform GMP compliance at clinical phase I scale, the scale-up toward late-stage and commercial batch production as well as platform expansion usefulness towards different cell lines.
The ACROBAT project will enable us to be aligned with industrial players roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities. Hence, EVerZom intends to achieve key milestones during the next 2 years including the validation of platform GMP compliance at clinical phase I scale, the scale-up toward late-stage and commercial batch production as well as platform expansion usefulness towards different cell lines.
The ACROBAT project will enable us to be aligned with industrial players roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190194936 |
| Start date: | 01-05-2022 |
| End date: | 30-04-2024 |
| Total budget - Public funding: | 2 487 651,25 Euro - 1 700 000,00 Euro |
Cordis data
Original description
EVerZom has developed a patented, fast, cost-effective, large-scale standardized extracellular vesicles (EV) production process to address the manufacturing issues that hamper EV translation towards clinic. EVerZom has performed a successful platform scale-up to 6L, meeting quantities needed for phase I trials, placing it at least 2 years ahead of known competitors.With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities. Hence, EVerZom intends to achieve key milestones during the next 2 years including the validation of platform GMP compliance at clinical phase I scale, the scale-up toward late-stage and commercial batch production as well as platform expansion usefulness towards different cell lines.
The ACROBAT project will enable us to be aligned with industrial players roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
